Search

Fosnetupitant

In April 2018, the U.S. … Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies [A32865].

Cilastatin

Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4. … [L7628] A newer triple-drug product was approved in July 2019 under the trade name Recarbrio which also contains [relebactam].[L4894]

Cobimetinib

It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction

Spectinomycin

An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.

Foreskin fibroblast (neonatal)

Dermagraft was introduced in the United Kingdom in October 1997, and several other European countries, as well as New Zealand and Australia. … Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997.

Obecabtagene autoleucel

[A265040,A265045] It works by targeting B-cell-specific CD19 surface markers present on malignant B cells. … [L52450] Obecabtagene autoleucel was also investigated in other hematological cancers and systemic lupus erythematosus.[A265045]

Pyrophosphoric acid

Hydroxychloroquine

Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer.[A183047] Hydroxychloroquine is an aminoquinoline like [chloroquine]. … [A192132] **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.

Obinutuzumab

[A274641] As a result, obinutuzumab induces greater antibody-dependent cellular cytotoxicity (ADCC) and a higher degree of direct cell death compared to rituximab. … [L54521] Like other drugs in its class, obinutuzumab targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes, mediating B-cell lysis.

Lonafarnib

Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature … aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.